Monolithic Power Systems Inc vs Pfizer Inc — how do they compare? Monolithic Power Systems Inc trades at $1,403.23 (market cap $67.87B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Pfizer Inc is far larger — about 2.3× Monolithic Power Systems Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.
| MPWR | PFE | |
|---|---|---|
Market Cap | $67.87B | $154.18B |
Sector | Utilities | Health |
52-Week High | $1.69K | $28.56 |
52-Week Low | $797.51 | $23.60 |
Enterprise Value | $66.48B | $205.67B |
Dividend Yield | 0.58% | 6.36% |
Volume | — | 29,869,932 |
Signals from Pluang's Aura AI — not financial advice
Monolithic Power Systems (MPWR) trades at $1,401.54, up 3.12% today, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend, supported by robust fundamentals including 24.5% net income margin and 21.98% ROE. Recent Q2 2026 results showed EPS of $6.50, exceeding estimates, with revenue growth driven by AI infrastructure demand. Analyst sentiment remains overwhelmingly positive with 88% buy ratings.
The outlook for MPWR is favorable due to accelerating AI-driven revenue and expanding margins, though high valuation multiples (P/E 84.26) pose a risk if growth slows. Investor optimism is tempered by potential overvaluation and sensitivity to tech sector volatility. The consensus price target of $1,870 suggests upside, but execution risks and competitive pressures warrant caution.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Trailing returns across standard periods
Latest headlines on both assets
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →